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LETTERS TO THE EDITORAORTIC BIOPROSTHESIS—
AVOID OBSTRUCTIVE
PROPERTIES DUE TO
THROMBOSIS AS ALTERED
DURABILITY DUE TO
STRUCTURALVALVE
DETERIORATION
To the Editor:
The brief communication entitled
‘‘Early stenosis of Medtronic Mosaic
porcine valves in the aortic position’’
by Lawton and colleagues1 was pub-
lished in the June issue of the Journal.
The authors reported 4 cases of early
altered durability of the aortic Med-
tronic Mosaic porcine bioprosthesis
causing stenosis of undetermined
cause after university site and manu-
facturer pathological evaluations.
At the time the article was in press,
we were visiting the California facility
of Medtronic, Inc, examining the pros-
thesis explants from the 6 longitudinal
study centers in preparation for the
meeting of the Society of Heart Valve
Disease. We had the opportunity to
view photographs of the valves (2 pre-
sented in color reproduction in the ar-
ticle) and to review the pathological
reports. The reports documented pan-
nus overgrowth of up to 3 mm from
the margins of the prosthesis sewing
cuff onto the leaflets of all 4 valves.
Two of the valves had evidence of co-
agulated blood partially in the outflow
of the cusps, whereas the other 2 had
extensive host thrombotic material fill-
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in 4 of 106 patients with the Mosaic
prosthesis. The study cohort of 106
aortic patients was accrued between
August 17, 2001, and December 5,
2005. We noted from Table 1 of the
communication that patient D had an
implant date in 2007. We further
learned that only 2 of the 4 valves dis-
cussed in the communication were im-
planted in the reporting center, only
one with complete thrombosis of the
prosthesis, thus resulting in a ratio of
1 of 106 patients.
The radiographs were reported as part
of the pathological reports, showing
no mineralization of valve tissue in 3
and remnants of mineralization of host
tissue on the sewing ring of the other
prosthesis.
The magnitude of prosthesis throm-
bosis has been previously reported by
us. In 2004, Fradet and associates,2
reporting on the 1029 patients in the
6-center longitudinal study, identified
3 cases of aortic prosthesis thrombosis
and no cases of structural valve deteri-
oration.
In 2005, Jamieson and coworkers,3
reporting on 657 patients from the
University of British Columbia, con-
firmed 3 cases of thrombosis (2 aortic
and 1 mitral) and 4 cases of structural
valve deterioration (3 with tears and
mild/moderate calcification and 1
with severe calcification accompany-
ing renal failure).
We agree with the authors that caus-
ative factors of thrombosis have not
been determined, except that Riess
and associates4 have reported abnor-
mal coagulation profile.
The ‘‘Guidelines for reporting mor-
tality and morbidity after cardiac valve
interventions’’5 clarifies structural
valve deterioration (referring to altered
durability), thrombosis, and nonstruc-
tural dysfunction. Lawton and col-
leagues1 are considering pannus
(nonstructural dysfunction) and throm-
bosis as durability issues. In these el-
derly patients (>70 years of age) there
is no evidence of structural valve dete-
rioration representing early altered du-Cardiovascular Surgery c May 2010rability. The thrombosis cause requires
further investigation and coagulation
evaluation on a case-by-case basis.
W. R. Eric Jamieson, MD
Guy J. Fradet, MD
Department of Surgery
University of British Columbia
Vancouver, British Columbia
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EXPERIENCE WITH THE
BIOCOR
PORCINE BIOPROSTHESIS
To the Editor:
With greatest interest we read the re-
cent article by Drs Myke´n and Bech-
Hausen.1 The authors reported on
a 20-year experience of 1712 patients
with the Biocor porcine bioprosthesis.
The study reported excellent long-term
prosthetic valve durability in both the
aortic and mitral positions over a 20-
year period. Comparing the data with
those for other types of bioprostheses,
the Biocor devices were shown to rival
the best valves around.
A few comments and a word of cau-
tion seem to be appropriate and of in-
terest to the readership of the Journal
to interpret these data. The authors
correctly state that comparisons with
Letters to the Editorother long-term studies are difficult
because of differing baseline charac-
teristics.1 Comparisons are subse-
quently provided and summarized in
Table 5; however, considerations con-
cerning some key patient cohort dif-
ferences are lacking.2-4 These include
the following.
First, the continuing patient enroll-
ment during a 20-year period resulted
in a limited mean follow-up time:
6.0 4.5 years for aortic valve replace-
ment (AVR) and 6.2  5.6 years for
mitral valve replacement. This strategy
tends to underestimate events in
comparison with similar studies with
a much shorter enrollment period like
the cited 20-year Edwards Clinical
Communique´, which had a mean
follow-up time of 9.0  5.5 years.2
Second, the authors report the actu-
arial freedom from reoperation because
of structural valve deterioration (SVD),
which is inherently lower than the free-
dom from SVD. Therefore the direct
comparison with the freedom from
SVD as reported by several other stud-
ies tends to underestimate the number
of events in the current study.3,4
Third, the long inclusion period has
resulted in an uneven age distribution
over time. Given the mean age differ-
ence between the originally reported
10-year experience and the current
20-year report, patients in the AVR
and mitral valve replacement cohorts,
respectively, must on average have
been about 7 and 5 years older during
the second decade of the study than dur-
ing the first decade.1,5 Therefore a high
number of patients with a relatively
short follow-up time might contribute
to an underestimation of the incidence
of SVD in the elderly groups.2
A further comment is directed at the
intriguing incompleteness of Table 5.1
Age-stratified event rates for AVR
from several studies are cited in the
last column, headed by the Biocor’s
20-year freedom from reoperation be-
cause of SVD being 92.1%  3.9%
in patients aged 65 years and older andThe Journal44.5%  9.2% in those younger than
65 years. However, for 2 studies these
readily available data are provided as
mean overall rates only.3,4 The excel-
lence of these results in the elderly pa-
tient groups makes these data
indispensable for the overall perspec-
tive. The 68%  12% overall freedom
from SVD in Aupart and colleagues’
18-year Perimount experience3 thus
breaks down into 99%  1% for pa-
tients aged greater than 70 years, 77%
 12% for those aged 60 to 70 years,
and 45%  15% for those aged less
than 60 years. In Yankah and associates’
17-year Mitroflow experience,4 the
67.0%  4.9% freedom from SVD in
similar age groups breaks down into
93.0%  3.0%, 60.1%  6.4%, and
45.7%  13.5%, respectively.
We congratulate the authors with
the realization of their study spanning
so many years and hope to see further
results and adequate comparisons in
future publications.
Willem J.L. Suyker, MD, PhD
Frans G. Leicher, MD
Department of Cardiothoracic
Surgery
Isala Clinics
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CARDIAC SURGERY
To the Editor:
I thank Dr Zamvar for his apprecia-
tive comments1 on my editorial entitled
‘‘The second assistant in cardiac sur-
gery: the challenges and answers.’’2
As Dr Zamvar rightly points out, the
position of second assistant is to be
seen as a great opportunity for surgical
training and not a burden. As surgical
trainees, we often have the mindset
that surgical training is all about cutting
and suturing, of doing rather than
watching. The second assistant position
in a way enforces a temporary pause in
this ‘‘cutting and suturing’’ ritual, al-
lowing the trainee to think and redefine
his or her techniques. Indeed, it is very
easy for the mind to drift, and the
trainee has to make a conscious effort
to stay focused. The ability to make
sharp observations and stay focused
for long durations is often not an innate
skill and has to be developed over time.
These mental faculties are as important
as hand skills in the making of a good
surgeon. The second assistant position
offers a unique opportunity to develop
these skills. I also agree with Dr Zam-
var that the new laws enforcing limited
hours of working on trainees3 will take
away a great opportunity from the cur-
rent generation of surgical trainees.
T. K. Susheel Kumar, MD
Department of Cardiovascular
Surgery
Children’s National Medical Centre
Washington, DCReferences
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